The success of its use in HER2-mutant NSCLC was demonstrated in the DESTINY-Lung02 phase II study, leading to FDA-accelerated approval of its use for previously treated metastatic or unresectable NSCLC on 11 August 2022 [35]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.